| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2023 | ALESSA THERAPEUTICS INC | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | R43CA281493 | Prostate Specific Anti-androgen Therapy for Localized Prostate Cancer | 000 | 1 | NIH | 10/8/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $405,680 ) |
| | 2023 | 2023 | ALESSA THERAPEUTICS INC | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | R43CA281493 | Prostate Specific Anti-androgen Therapy for Localized Prostate Cancer | 000 | 1 | NIH | 7/21/2023 | $405,681 |
| | 2023 | 2021 | ALESSA THERAPEUTICS INC | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | R43CA257773 | A novel implantable drug-eluting device that delivers an anti-androgen to the prostate to treat localized early stage prostate cancer | 000 | 1 | NIH | 6/20/2023 | -$1 |
|
| Issue Date FY: 2021 ( Subtotal = $393,713 ) |
| | 2021 | 2021 | ALESSA THERAPEUTICS, INC. | 930 BRITTAN AVE | SAN CARLOS | CA | 94070-4002 | SAN MATEO | USA | R43CA257773 | A novel implantable drug-eluting device that delivers an anti-androgen to the prostate to treat localized early stage prostate cancer | 000 | 1 | NIH | 8/4/2021 | $393,713 |
|
|
